Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity

被引:170
作者
Sasaki, T
Larsson, H
Tisi, D
Claesson-Welsh, L
Hohenester, E
Timpl, R [1 ]
机构
[1] Max Planck Inst Biochem, D-82152 Martinsried, Germany
[2] Rudbeck Lab, Dept Genet & Pathol, S-75185 Uppsala, Sweden
[3] Univ London Imperial Coll Sci Technol & Med, Blackett Lab, London SW7 2BW, England
基金
英国惠康基金;
关键词
angiogenesis inhibition; binding properties; recombinant fragments; tissue expression; X-ray structure;
D O I
10.1006/jmbi.2000.3996
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Endostatin is a fragment of the C-terminal domain NC1 of collagen XVIII that inhibits angiogenesis and tumor growth. We report the characterization of a collagen XV endostatin analogue and its parent NC1 domain, obtained by recombinant expression in mammalian cells. Both NC1 domains contain a trimerization domain, a hinge region that is more sensitive to proteolysis in collagen XVIII and the endostatin domain. Unlike endostatin-XVIII, endostatin-Xr does not bind zinc or heparin, which is explained by the crystal structure of endostatin-XV, The collagen XV and XVIII fragments inhibited chorioallantoic membrane angiogenesis induced by basic fibroblast growth factor (FGF-2) or vascular endothelial growth factor (VEGF), but there are striking differences depending on which cytokine is used and whether free endostatins or NC1 domains are applied. The collagen XV and XVIII fragments showed a similar binding repertoire for extracellular matrix proteins. Differences were found in the immunohistological localization in vessel walls and basement membrane zones. Together, these data indentify endostatin-XV as an angiogenesis inhibitor, which differs from endostatin-XVIII in several important functional details. (C) 2000 Academic Press.
引用
收藏
页码:1179 / 1190
页数:12
相关论文
共 62 条
[1]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[2]   Vascular development: Cellular and molecular regulation [J].
Beck, L ;
DAmore, PA .
FASEB JOURNAL, 1997, 11 (05) :365-373
[3]   Zinc-binding of endostatin is essential for its antiangiogenic activity [J].
Boehm, T ;
O'Reilly, MS ;
Keough, K ;
Shiloach, J ;
Shapiro, R ;
Folkman, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 252 (01) :190-194
[4]   Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J].
Boehm, T ;
Folkman, J ;
Browder, T ;
OReilly, MS .
NATURE, 1997, 390 (6658) :404-407
[5]   REQUIREMENT OF VASCULAR INTEGRIN ALPHA(V)BETA(3) FOR ANGIOGENESIS [J].
BROOKS, PC ;
CLARK, RAF ;
CHERESH, DA .
SCIENCE, 1994, 264 (5158) :569-571
[6]  
BRUNGER AT, 1992, XPLOR VERSION 3 1 SY
[7]  
Cao Y, 1998, Prog Mol Subcell Biol, V20, P161
[8]   Kringle domains of human angiostatin - Characterization of the anti-proliferative activity on endothelial cells [J].
Cao, YH ;
Ji, RW ;
Davidson, D ;
Schaller, J ;
Marti, D ;
Sohndel, S ;
McCance, SG ;
OReilly, MS ;
Llinas, M ;
Folkman, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (46) :29461-29467
[9]   THE 16-KILODALTON N-TERMINAL FRAGMENT OF HUMAN PROLACTIN IS A POTENT INHIBITOR OF ANGIOGENESIS [J].
CLAPP, C ;
MARTIAL, JA ;
GUZMAN, RC ;
RENTIERDELRUE, F ;
WEINER, RI .
ENDOCRINOLOGY, 1993, 133 (03) :1292-1299
[10]   CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells [J].
Dawson, DW ;
Pearce, SFA ;
Zhong, RQ ;
Silverstein, RL ;
Frazier, WA ;
Bouck, NP .
JOURNAL OF CELL BIOLOGY, 1997, 138 (03) :707-717